Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers

Oncogene volume 24, pages 7946–7952 (2005)Cite this article

Abstract

Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers. Wnt antagonists have recently attracted wide attention. Wnt inhibitory factor-1 (WIF-1) is a secreted antagonist that can bind to Wnt proteins directly and inhibit Wnt signaling pathway. It has been reported that WIF-1 expression is down regulated in several solid tumors and that WIF-1 is silenced by promoter hypermethylation in lung and colorectal cancer. By using RT–PCR, bisulfite sequence analysis, and methylation-specific PCR, we analysed expression and methylation of WIF-1 in cancer cell lines and freshly resected cancer tissues of the esophagus, stomach, colorectum, and pancreas. Downregulation of WIF-1 mRNA expression was observed in 61 (91.0%) of 67 cancer cell lines, 16 (80.0%) of 20 esophageal, 23 (74.2%) of 31 gastric, 41 (82.0%) of 50 colorectal, and six (75.0%) of eight pancreatic cancer tissues. Downregulation of WIF-1 expression was also observed at protein level. No significant association between WIF-1 downregulation and clinicopathological characteristics was found, suggesting that downregulation of WIF-1 expression is an early event in carcinogenesis of these cancers. Indeed, downregulation of WIF-1 expression was observed in 32 (72.7%) of 44 colorectal adenoma tissues and 18 (78.2%) of 23 early mucosal or submucosal colorectal carcinoma tissues. CpG island hypermethylation in the WIF-1 promoter region correlated with downregulation of WIF-1 expression in cancer cell lines and tissues. Treatment with demethylating agent, 5-aza-2′-deoxycytidine (5-aza-dC), restored WIF-1 expression in cancer cell lines. A combined treatment of 5-aza-dC and a histone deacetylase inhibitor, trichostatinA, restored WIF-1 expression synergistically, indicating the role of cytosine methylation and histone deacetylation in the silencing of the WIF-1 gene. Transfection of the WIF-1 gene construct into TE-1 esophageal cancer cell lines or SW48 colon cancer cell lines lacking WIF-1 expression resulted in a significant inhibition on colony formation, cell proliferation, anchorage-independent growth in soft agar. TOPflash assay showed WIF-1 inhibits Wnt canonical signaling in these cell lines. These results suggest tumor suppressive function of WIF-1, due to its ability to inhibit Wnt signaling. Our results suggest that WIF-1 silencing due to promoter hypermethylation is an important mechanism underlying aberrant activation of the Wnt signaling pathway in carcinogenesis of the digestive organs. Modulation of the Wnt pathway, through reversal of WIF-1 silencing by demethylating agents, is a potential target for treatment and/or prevention of gastrointestinal cancers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM and Morton DG . (2004). Cancer Res., 64, 883–888.

  • Cameron E, Bachman KE, Myohanen S, Herman JG and Baylin SB . (1999). Nat. Genet., 21, 103–107.

  • Cebrat M, Strzadala L and Kisielow P . (2004). Cancer Lett., 206, 107–113.

  • Giles RH, van Es JH and Clevers H . (2003). Biochem. Biophys. Acta., 1653, 1–24.

  • He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, Mikami I, McCormick F and Jablons DM . (2005). Oncogene, 24, 3054–3058.

  • Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.

  • Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T and Truong T . (2002). Mol. Pathol., 55, 220–226.

  • Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB and Nathans J . (1999). Nature, 398, 431–436.

  • Ikenoue T, Ijichi H, Kato N, Kanai F, Masaki T, Rengifo W, Okamoto M, Matsumura M, Kawabe T, Shiratori Y and Omata M . (2002). Jpn. J. Cancer Res., 93, 1213–1220.

  • Katoh M . (2001). Int. J. Oncol., 19, 1003–1007.

  • Kawano Y and Kypta R . (2003). J. Cell Sci., 116, 2627–2634.

  • Kirikoshi H, Sekihara H and Katoh M . (2001). Int. J. Oncol., 19, 1221–1225.

  • Kolligs FT, Bommer G and Goke B . (2002). Digestion, 66, 131–144.

  • Lustig B and Behrens J . (2003). J. Cancer Res. Clin. Oncol., 129, 199–221.

  • Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F and Jablons DM . (2004). Cancer Res., 64, 4717–4720.

  • Mizushima T, Nakagawa H, Kamberov YG, Wilder EL, Klein PS and Rustgi AK . (2002). Cancer Res., 62, 277–282.

  • Reguart N, He B, Xu Z, You L, Lee AY, Mazieres J, Mikami I, Batra S, Rosell R, McCormick F and Jablons DM . (2004). Biochem. Biophys. Res. Commun., 323, 229–234.

  • Saitoh T, Mine T and Katoh M . (2002). Int. J. Mol. Med., 9, 515–519.

  • Smith K, Bui TD, Poulsom R, Kaklamanis L, Williams G and Harris AL . (1999). Br. J. Cancer, 81, 496–502.

  • Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG and Baylin SB . (2002). Nat. Genet., 31, 141–149.

  • Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Dong Chen W, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG and Baylin SB . (2004). Nat. Genet., 36, 417–422.

  • Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A and Pilarsky C . (2003). J. Pathol., 201, 204–212.

Download references

Acknowledgements

This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (HY and KI), and Ministry of Health, Labor and Welfare of Japan (HY and KI).

Author information

Author notes

  1. Hiroaki Taniguchi and Hiroyuki Yamamoto: These two authors contributed equally to this work

Authors and Affiliations

  1. First Department of Internal Medicine, Sapporo Medical University, South-1, West-16, Chuo-ku, Sapporo, 060-8543, Hokkaido, Japan

    Hiroaki Taniguchi, Hiroyuki Yamamoto, Tamaki Hirata, Nobuki Miyamoto, Mariko Oki, Katsuhiko Nosho, Yasushi Adachi, Takao Endo, Kohzoh Imai & Yasuhisa Shinomura

Authors
  1. Hiroaki Taniguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroyuki Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tamaki Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nobuki Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mariko Oki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katsuhiko Nosho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasushi Adachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takao Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kohzoh Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasuhisa Shinomura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroyuki Yamamoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taniguchi, H., Yamamoto, H., Hirata, T. et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24, 7946–7952 (2005). https://doi.org/10.1038/sj.onc.1208910

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208910

Keywords

Search

Advanced search

Quick links